Introducing Contineum Therapeutic’s PIPE-791 a Validated LPA1R Antagonist in IPF
- Targeting the lysophosphatidic acid 1 receptor (LPA1R), a clinically validated driver of f ibrosis, to disrupt fibroblast recruitment, vascular leak, and pro-fibrotic signalling in IPF
- Reviewing preclinical findings and early clinical data supporting PIPE-791, including differentiation strategy within the LPA1R class and considerations for dose, safety, and patient selection
- Evaluating whether next-generation LPA1R antagonism can overcome historical development challenges and how this programme may fit within combination strategies and evolving standards of care